Estrella Immunopharma Inc. (NASDAQ:ESLA) — Market Cap & Net Worth
Market Cap & Net Worth: Estrella Immunopharma Inc. (ESLA)
Estrella Immunopharma Inc. (NASDAQ:ESLA) has a market capitalization of $27.75 Million ($27.75 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24135 globally and #5196 in its home market, demonstrating a -0.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Estrella Immunopharma Inc.'s stock price $0.64 by its total outstanding shares 43497864 (43.50 Million). Also see Estrella Immunopharma Inc. balance sheet assets for a full breakdown of the balance sheet.
Estrella Immunopharma Inc. Market Cap History: 2021 to 2026
Estrella Immunopharma Inc.'s market capitalization history from 2021 to 2026. Data shows change from $431.06 Million to $27.83 Million (-41.95% CAGR). Also see Estrella Immunopharma Inc. (ESLA) cash conversion ratio for how efficiently the company converts equity into cash flow.
Index Memberships
Estrella Immunopharma Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #685 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2255 of 3165 |
Weight: Estrella Immunopharma Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Estrella Immunopharma Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Estrella Immunopharma Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Estrella Immunopharma Inc. stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ESLA by Market Capitalization
Companies near Estrella Immunopharma Inc. in the global market cap rankings as of September 18, 2026. Review Estrella Immunopharma Inc. (ESLA) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Estrella Immunopharma Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Estrella Immunopharma Inc. Historical Marketcap From 2021 to 2026
Between 2021 and today, Estrella Immunopharma Inc.'s market cap moved from $431.06 Million to $ 27.83 Million, with a yearly change of -41.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $27.83 Million | -58.98% |
| 2025 | $67.86 Million | +30.00% |
| 2024 | $52.20 Million | +8.11% |
| 2023 | $48.28 Million | -89.21% |
| 2022 | $447.59 Million | +3.83% |
| 2021 | $431.06 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Estrella Immunopharma Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $27.75 Million USD |
| MoneyControl | $27.75 Million USD |
| MarketWatch | $27.75 Million USD |
| marketcap.company | $27.75 Million USD |
| Reuters | $27.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Estrella Immunopharma Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leuke… Read more